Holen Sie sich die Stockscreener-App
2.86
8.33%
0.22
Schlusskurs vom Vortag:
$2.64
Offen:
$2.71
24-Stunden-Volumen:
569.25K
Relative Volume:
0.77
Marktkapitalisierung:
$204.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-104.08M
KGV:
-2.0328
EPS:
-1.4069
Netto-Cashflow:
$-89.91M
1W Leistung:
+3.62%
1M Leistung:
+6.72%
6M Leistung:
+62.50%
1J Leistung:
+57.14%
1-Tages-Spanne:
$2.65
$2.875
1-Wochen-Bereich:
$2.58
$2.99
52-Wochen-Spanne:
$1.63
$3.65
Nkarta Inc Stock (NKTX) Company Profile
Firmenname
Nkarta Inc
Sektor
Branche
Telefon
(925) 407-1049
Adresse
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.86 | 204.62M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-09 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-08-14 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-28 | Eingeleitet | Needham | Buy |
| 2022-07-18 | Eingeleitet | SVB Leerink | Outperform |
| 2022-03-11 | Eingeleitet | Raymond James | Outperform |
| 2022-03-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-06 | Eingeleitet | William Blair | Outperform |
| 2021-11-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2020-08-04 | Eingeleitet | Cowen | Outperform |
| 2020-08-04 | Eingeleitet | Evercore ISI | Outperform |
| 2020-08-04 | Eingeleitet | Mizuho | Buy |
| 2020-08-04 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nkarta Inc Aktie (NKTX) Neueste Nachrichten
Nkarta Inc (NKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nkarta Inc (NKTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nkarta Inc (NKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NKTX Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Clinical ProgressEarnings Quality Score - newsline.com
Nkarta Inc (NKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nkarta Inc (NKTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nkarta Inc (NKTX) Institutional Confidence - TradingKey
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss and Promising Pipeline Updates Spark 12% Rally - newsline.com
Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay - TipRanks
Nkarta (NKTX) investors approve directors, auditor and annual say-on-pay - Stock Titan
Nkarta (NASDAQ: NKTX) reports 37,000-share option grant tied to RA Capital - Stock Titan
Nkarta (NKTX) director awarded 37,000 stock options vesting in 2027 - Stock Titan
Nkarta (NKTX) director George Simeon awarded 37,000-share stock option grant - Stock Titan
Nkarta (NKTX) director receives stock options on 37,000 common shares - Stock Titan
Nkarta (NKTX) director granted 37,000 stock options for RA Capital funds - Stock Titan
Nkarta director granted options on 37,000 shares | NKTX Insider Trading - Stock Titan
Nkarta (NKTX) director awarded stock options for 37,000 shares at $2.46 - Stock Titan
Nkarta (NKTX) director Angela Thedinga awarded 37,000 stock options - Stock Titan
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineFree Cash Flow Trends - newsline.com
Nkarta Inc. (NKTX) Edges Lower: Assessing Support and Resistance in a Volatile Biotech MarketDefined Outcome ETF - newsline.com
NKTX stock up on upbeat regulatory update on lead autoimmune program - MSN
Nkarta Inc. (NKTX) Edges Higher on Above-Average Volume, Nears Key ResistanceDealer Positioning - newsline.com
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressTech Earnings Analysis - The Legal Advocate
NKTX Q1 2026 Earnings: Narrower-than-expected loss lifts sharesReturn On Capital - newsline.com
Nkarta Inc. (NKTX) Rallies 3.45% as Buyers Defend Key Support LevelSign of Strength - thelegaladvocate.com
Nkarta’s NK Cell Therapy Push Moves Into Outpatient Care - Finimize
Nkarta Inc. (NKTX) Advances 4.25% as Biotech Sector Momentum BuildsMESA MA - thelegaladvocate.com
Nkarta Inc. (NKTX) Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Advances Pipeline - The Legal Advocate
Nkarta Inc. (NKTX) Holds Steady at $3.03 as Market Awaits CatalystATR Stop - Newser
Nkarta (NKTX) Posts Record Q1 2026 — EPS $-0.37 Blows Past EstimatesRising Community Picks - newser.com
NEA (NKTX) drops below 5% ownership in latest Schedule 13D/A filing - Stock Titan
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes - PR Newswire Canada
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m - simplywall.st
Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation - Yahoo Finance
Nkarta Price Target Maintained With a $11.00/Share by Needham - Moomoo
Nkarta, Inc. Stock 12‑Month Price Target Raised to $11.8, Implies 260% Upside - TradingView
Nkarta (NASDAQ:NKTX) Q1 2026 Narrower Loss Beats Estimates as Autoimmune Trial Advances - ChartMill
Nkarta (NASDAQ: NKTX) Q1 2026 loss narrows as cash reaches $266.7M - Stock Titan
Nkarta Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results - Weekly Voice
Nkarta (NKTX) Q1 2026 results: NKX019 trial progress and cash runway into 2029 - Stock Titan
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
TradingKey - TradingKey
How Nkarta (NKTX) performance compares to expectations (Momentum Fading) 2026-05-08Social Buzz - newser.com
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by Analysts - MarketBeat
NKTX Q1'26 Earnings: revenue estimate is 0 USD - TradingView
NKTX Nkarta reports wider than expected Q4 2025 loss, shares fall nearly 3% on weak investor sentiment.AI Stock Signals - Newser
Finanzdaten der Nkarta Inc-Aktie (NKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):